US20451W1018 - ADR
NASDAQ:CMPS (1/30/2023, 7:00:00 PM)-0.25 (-2.34%)
|GICS Sector||Health Care|
|Earnings (Last)||11-03 2022-11-03/bmo||Earnings (Next)||N/A N/A|
|Ins Owners||20.56%||Inst Owners||19.47%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Compass Pathways Plc functions as an investment holding company. The company is headquartered in Altrincham, Cheshire and currently employs 116 full-time employees. The company went IPO on 2020-09-18. The firm is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The firm has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The firm's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. Its randomized controlled Phase IIb study of psilocybin therapy in treatment-resistant depression is the psilocybin therapy clinical trial, with approximately 233 patients across 22 sites in 10 European and North American countries. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The firm is also running a Phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD).
COMPASS PATHWAYS PLC
3Rd Floor, 1 Ashley Road, Altrincham
Altrincham CHESHIRE WA14 2DT
CEO: George Goldsmith
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
/PRNewswire/ -- Even during the recent global supply chain problems, certain markets have continued to show growth. The psychedelic drugs markets is one of...
A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12 billion before 2030.
Here you can normally see the latest stock twits on CMPS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.